title: Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept.
abstract: The aim of this study was to demonstrate that oligo-branched peptides can be effective either for spotlighting tumor cells that overexpress peptide receptors, or for killing them, simply by exchanging the functional moiety coupled to the conserved receptor-targeting core. Tetra-branched peptides containing neurotensin (NT) sequence are described here as selective targeting agents for human colon, pancreas and prostate cancer. Fluorophore-conjugated peptides were used to measure tumor versus healthy tissue binding in human surgical samples, resulting in validation of neurotensin receptors as highly promising tumor-biomarkers. Drug-armed branched peptides were synthesized with different conjugation methods, resulting in uncleavable adducts or drug-releasing molecules. Cytotoxicity on human cell lines from colon (HT-29), pancreas (PANC-1) or prostate (PC-3) carcinoma indicated branched NT conjugated with MTX and 5-FdU as the most active agents on PANC-1 (EC(50) 4.4e-007 M) and HT-29 (1.1e-007 M), respectively. Tetra-branched NT armed with 5-FdU was used for in vivo experiments in HT-29-xenografted mice and produced a 50% reduction in tumor growth with respect to animals treated with the free drug. An unrelated branched peptide carrying the same drug was completely ineffective. In vitro and in vivo results indicated that branched peptides are valuable tools for tumor selective targeting.
authors.affiliation: Department of Molecular Biology, University of Siena, Siena, Italy. chiarafalciani@unisi.it
authors.forename: C
authors.initials: C
authors.lastname: Falciani
authors.forename: B
authors.initials: B
authors.lastname: Lelli
authors.forename: J
authors.initials: J
authors.lastname: Brunetti
authors.forename: S
authors.initials: S
authors.lastname: Pileri
authors.forename: A
authors.initials: A
authors.lastname: Cappelli
authors.forename: A
authors.initials: A
authors.lastname: Pini
authors.forename: C
authors.initials: C
authors.lastname: Pagliuca
authors.forename: N
authors.initials: N
authors.lastname: Ravenni
authors.forename: L
authors.initials: L
authors.lastname: Bencini
authors.forename: S
authors.initials: S
authors.lastname: Menichetti
authors.forename: R
authors.initials: R
authors.lastname: Moretti
authors.forename: M
authors.initials: M
authors.lastname: De Prizio
authors.forename: M
authors.initials: M
authors.lastname: Scatizzi
authors.forename: L
authors.initials: L
authors.lastname: Bracci
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001692:Biological Transport; D014408:Biomarkers, Tumor / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009496:Neurotensin / Q000031:analogs & derivatives*; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D018000:Receptors, Peptide / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004337:Drug Carriers; D009842:Oligopeptides; D018000:Receptors, Peptide; D009496:Neurotensin